Macrophage migration inhibitory factor: critical role in obesity, insulin resistance, and associated comorbidities
- PMID: 20169173
- PMCID: PMC2821632
- DOI: 10.1155/2010/610479
Macrophage migration inhibitory factor: critical role in obesity, insulin resistance, and associated comorbidities
Abstract
Obesity is associated with insulin resistance, disturbed glucose homeostasis, low grade inflammation, and comorbidities such as type 2 diabetes and cardiovascular disease. The cytokine macrophage migration inhibitory factor (MIF) is an ubiquitously expressed protein that plays a crucial role in many inflammatory and autoimmune disorders. Increasing evidence suggests that MIF also controls metabolic and inflammatory processes underlying the development of metabolic pathologies associated with obesity. This is a comprehensive summary of our current knowledge on the role of MIF in obesity and obesity-associated comorbidities, based on human clinical data as well as animal models of disease.
References
-
- Kelly T, Yang W, Chen C-S, Reynolds K, He J. Global burden of obesity in 2005 and projections to 2030. International Journal of Obesity. 2008;32(9):1431–1437. - PubMed
-
- Yusuf PS, Hawken S, Ounpuu S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. The Lancet. 2004;364(9438):937–952. - PubMed
-
- Despres J-P, Lemieux I, Bergeron J, et al. Abdominal obesity and the metabolic syndrome: contribution to global cardiometabolic risk. Arteriosclerosis, Thrombosis, and Vascular Biology. 2008;28(6):1039–1049. - PubMed
-
- Després J-P. Is visceral obesity the cause of the metabolic syndrome? Annals of Medicine. 2006;38(1):52–63. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
